Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
about
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPHDistinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolitesReactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosisFactors determining sensitivity and resistance of tumor cells to arsenic trioxideAlterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myelomaAn inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsIncreased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockadeEffect of arsenic trioxide on human hepatocarcinoma in nude mice.Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway.Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells.Apoptosis of multiple myeloma.PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cellsTRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.Reciprocal complementation of the tumoricidal effects of radiation and natural killer cellsTetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells.Targeted therapy in multiple myeloma.Arsenic trioxide: an anti cancer missile with multiple warheads.Wogonin inhibits the proliferation of myelodysplastic syndrome cells through the induction of cell cycle arrest and apoptosis.Dietary NiCl₂ causes G₂/M cell cycle arrest in the broiler's kidney.BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment: Assessment of Apoptotic Mechanisms and Oxidative DamageThe role of TRAIL death receptors in the treatment of hematological malignancies.Current trends in multiple myeloma management.Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.Apoptosis in leukemias: regulation and therapeutic targeting.Arsenic trioxide induces ROS activity and DNA damage, leading to G0/G1 extension in skin fibroblasts through the ATM-ATR-associated Chk pathway.Nuclear translocation of nuclear factor kappa B is regulated by G protein signaling pathway in arsenite-induced apoptosis in HBE cell line.Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell lineInvolvement of E2F1 transcriptional activity in cadmium-induced cell-cycle arrest at G1 in human lung fibroblasts.Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells.Arsenite-induced apoptosis is prevented by selenite in A375 cell line.Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis.
P2860
Q24603767-8D374435-1135-451D-BCB1-0050B6BDA7FBQ25256850-CCB08750-FBCA-4581-B641-D747241058EAQ28388476-2FE890C0-055C-4DB3-ADF8-B30362F5C1CCQ28483625-4F88CD03-A99C-4C02-9F75-21DD4AE546D8Q28484542-8A4277B2-0380-434B-BA48-E95098303882Q28486021-CB094F25-14BA-49C9-B868-E012FC30D359Q28539684-8D62A022-00C8-4126-8866-E054DFFB11A4Q33208822-3ACB3671-F9D7-4BEC-B010-80D34AEF774DQ33218586-74250458-2A2F-4664-A775-A7033BA16600Q33827724-23EDED95-212E-4CBA-AA50-441F8BFDC528Q33930178-4D9DD690-0579-4C23-A6C3-45DC4ADAFE0DQ34543759-9D0C83B3-1F14-4154-B58A-3241ED79696AQ34564468-681974BC-E237-4B94-AF09-B9B07A841EEFQ34616652-46B5E2F9-9D5A-467E-9114-E9D1A1981777Q34698158-7EE53A16-9E81-441B-B5DB-379B7B8FBD37Q35674537-048DC0F6-F2D5-4A21-AEB8-44544AF1A592Q36108614-D6BF1E1A-3397-462A-9402-EC50BA6DD22CQ36194579-1B0298E8-DC74-407E-9C97-2884F9839CCCQ36224965-188A9A19-46AC-4109-A20D-6CB475E3CF90Q36546526-556EEB6B-E12A-4B27-9DFB-076E99410214Q36658048-503C5F49-844F-4179-804C-9B0D0D3734A5Q36868111-2C787BB9-EBB4-4277-8929-44BBFE1205B0Q37059750-C3CC2B30-4757-4EE0-A192-82074E0CC995Q37183557-DF8E12E0-1992-426A-A993-B628FDEFFF5CQ37451733-F89F32D7-19B9-402D-AC0D-10577D3D4A2BQ37715814-A2809B9E-2FF3-4518-8D40-A42F9AECF363Q38724393-50AA3632-AA8A-43D7-8B8C-284F12D21E7EQ38840886-11DE2E98-88F7-4AA7-AE29-840599A4851BQ38921254-64EBE6AE-C3EA-4ED8-9C48-E8BDA184AB0FQ38930818-8E0EF41B-311B-4994-8FC4-5794DD865020Q39114955-95B78677-9C50-4E6C-8F15-B64957FC3D33Q39200177-8A5F9989-7FA5-4B1A-87EF-0B703A1E3A61Q39540028-E38A8D19-C212-41F9-9FA8-6856D71C8917Q39569681-020CD1F2-743C-4858-8295-AA53787E81ACQ39656160-E1B298D7-7142-4D8B-A57E-D44C156C2B02Q39688844-00996C5A-0BAE-40DE-9B45-EE4F54467BD3Q39715045-64F9CCBC-27B1-491F-9951-8B418F6AA817Q39748970-4115FB34-2DFA-45F5-864F-CCB0CC8E77CBQ40070572-AAFCCE49-F92E-4739-B518-426CBB46EC61Q40131977-299858D4-9472-468B-B592-9891DCE66D86
P2860
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@ast
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@en
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@nl
type
label
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@ast
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@en
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@nl
prefLabel
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@ast
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@en
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@nl
P2093
P1433
P1476
Arsenic trioxide-induced apopt ...... , and synergy with APO2/TRAIL.
@en
P2093
Susan Hilsenbeck
Yair Gazitt
P304
P356
10.1182/BLOOD-2002-10-3231
P407
P577
2003-01-16T00:00:00Z